

Resource Summary Report

Generated by [dkNET](#) on Sep 16, 2026

Oncotator

RRID:SCR_005183

Type: Tool

Proper Citation

Oncotator (RRID:SCR_005183)

Resource Information

URL: <http://www.broadinstitute.org/cancer/cga/ncotator>

Proper Citation: Oncotator (RRID:SCR_005183)

Description: A tool for annotating human genomic point mutations and indels with data relevant to cancer researchers. Genomic Annotations, Protein Annotations, and Cancer Annotations are aggregated from many resources. A standalone version of Oncotator is being developed.

Abbreviations: Oncotator

Resource Type: analysis service resource, data analysis service, production service resource, service resource

Keywords: annotate, genomic, point mutation, indel, mutation, genome, protein, variant

Related Condition: Cancer

Resource Name: Oncotator

Resource ID: SCR_005183

Alternate IDs: OMICS_00178

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260912T200136+0000

Ratings and Alerts

No rating or validation information has been found for Oncotator.

No alerts have been found for Oncotator.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 223 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Camp SY, et al. (2026) Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss. Science advances, 12(8), eadv5457.

Kuo HH, et al. (2026) Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. Science advances, 12(26), eadz3351.

Ravillah D, et al. (2026) VSIG10L is a major determinant of esophageal homeostasis and inherited predisposition to Barrett's esophagus. Nature communications, 17(1).

Shi Y, et al. (2026) Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma. bioRxiv : the preprint server for biology.

Gentile C, et al. (2026) mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion. bioRxiv : the preprint server for biology.

Feng J, et al. (2026) Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study. Journal of translational medicine, 24(1).

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1835.

Yang W, et al. (2026) Clinically actionable stratification of uncommon MET fusions: a precision oncology framework. Journal of translational medicine, 24(1).

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Ghosh A, et al. (2025) Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours. Communications biology, 8(1), 207.

Zhong S, et al. (2025) Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine, 6(8), 102217.

K??bler K, et al. (2025) Tamoxifen induces PI3K activation in uterine cancer. *Nature genetics*, 57(9), 2192.

Liu Z, et al. (2025) Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. *The oncologist*, 30(11).

Zhang X, et al. (2025) Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. *Nature communications*, 16(1), 4398.

Sun W, et al. (2025) A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis. *Frontiers in immunology*, 16, 1607772.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Feng EM, et al. (2025) Racial variation in the advanced prostate cancer genome. *Prostate cancer and prostatic diseases*, 28(4), 902.

Yang Q, et al. (2025) Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function. *Scientific reports*, 15(1), 8437.

Lu S, et al. (2025) Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. *EClinicalMedicine*, 84, 103258.

Knight AD, et al. (2025) Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. *medRxiv : the preprint server for health sciences*.